Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer’s Aptivus Approved For HIV In Kids

This article was originally published in The Pink Sheet Daily

Executive Summary

New oral solution gets approval for adults, too.

You may also be interested in...



Lilly Prasugrel Delay Could Extend Well Into 2009

FDA is looking at a February advisory committee for Lilly/Daiichi anti-clotting drug. Safety issues are one potential topic.

Lilly Prasugrel Delay Could Extend Well Into 2009

FDA is looking at a February advisory committee for Lilly/Daiichi anti-clotting drug. Safety issues are one potential topic.

Boehringer Ingelheim’s HIV Therapy Aptivus Gets Full FDA Approval

Protease inhibitor received accelerated approval in June 2005, but FDA requested additional post-marketing trials.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel